Adolescents with obesity treated with exenatide maintain endogenous GLP-1, reduce DPP-4, and improve glycemic control
BackgroundGLP-1 receptor agonists (GLP-1RA) are increasingly used to treat adolescent obesity. However, the effect on endogenous GLP-1 secretory patterns following treatment in adolescents is unknown. The GLP-1RA exenatide was shown to significantly lower BMI and 2-hour glucose in adolescents with o...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-11-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2023.1293093/full |
| _version_ | 1827777028755030016 |
|---|---|
| author | Rasmus Stenlid Rasmus Stenlid Rasmus Stenlid Sara Y. Cerenius Quan Wen Banu Küçükemre Aydin Banu Küçükemre Aydin Hannes Manell Hannes Manell Azazul Chowdhury Hjalti Kristinsson Iris Ciba Iris Ciba Erik S. Gjessing Katharina Mörwald Katharina Mörwald Julian Gomahr Julian Gomahr Verena Heu Verena Heu Daniel Weghuber Daniel Weghuber Anders Forslund Anders Forslund Anders Forslund Peter Bergsten Peter Bergsten Peter Bergsten |
| author_facet | Rasmus Stenlid Rasmus Stenlid Rasmus Stenlid Sara Y. Cerenius Quan Wen Banu Küçükemre Aydin Banu Küçükemre Aydin Hannes Manell Hannes Manell Azazul Chowdhury Hjalti Kristinsson Iris Ciba Iris Ciba Erik S. Gjessing Katharina Mörwald Katharina Mörwald Julian Gomahr Julian Gomahr Verena Heu Verena Heu Daniel Weghuber Daniel Weghuber Anders Forslund Anders Forslund Anders Forslund Peter Bergsten Peter Bergsten Peter Bergsten |
| author_sort | Rasmus Stenlid |
| collection | DOAJ |
| description | BackgroundGLP-1 receptor agonists (GLP-1RA) are increasingly used to treat adolescent obesity. However, the effect on endogenous GLP-1 secretory patterns following treatment in adolescents is unknown. The GLP-1RA exenatide was shown to significantly lower BMI and 2-hour glucose in adolescents with obesity, in the placebo-controlled, randomized controlled trial Combat-JUDO. The aim of this study was to evaluate effects of weekly injections of 2 mg exenatide extended release on secretory patterns of endogenous hormones during OGTT.Subjects and MeasurementsThis study was a pre-planned sub-study of the Combat-JUDO trial, set at the Pediatric clinic at Uppsala University Hospital, Sweden and Paracelsus Medical University, Austria. 44 adolescents with obesity were included and randomized 1:1 to treatment:placebo. 19 patients in the treatment group and 18 in the placebo group completed the trial. Before and after treatment, GLP-1, glucose, insulin, glucagon and glicentin levels were measured during OGTT; DPP-4 and proinsulin were measured at fasting. A per-protocol approach was used in the analyses.ResultsExenatide treatment did not affect GLP-1 levels during OGTT. Treatment significantly lowered DPP-4, proinsulin and the proinsulin-to-insulin ratio at fasting, increased glicentin levels but did not affect insulin, C-peptide or glucagon levels during OGTT.ConclusionWeekly s.c. injections with 2 mg of exenatide maintains endogenous total GLP-1 levels and lowers circulating DPP-4 levels. This adds an argument in favor of using exenatide in the treatment of pediatric obesity.Clinical trial registrationclinicaltrials.gov, identifier NCT02794402 |
| first_indexed | 2024-03-11T14:12:33Z |
| format | Article |
| id | doaj.art-c0fe63dd77744e8b9f14af9a029087ce |
| institution | Directory Open Access Journal |
| issn | 1664-2392 |
| language | English |
| last_indexed | 2024-03-11T14:12:33Z |
| publishDate | 2023-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Endocrinology |
| spelling | doaj.art-c0fe63dd77744e8b9f14af9a029087ce2023-11-01T17:36:43ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922023-11-011410.3389/fendo.2023.12930931293093Adolescents with obesity treated with exenatide maintain endogenous GLP-1, reduce DPP-4, and improve glycemic controlRasmus Stenlid0Rasmus Stenlid1Rasmus Stenlid2Sara Y. Cerenius3Quan Wen4Banu Küçükemre Aydin5Banu Küçükemre Aydin6Hannes Manell7Hannes Manell8Azazul Chowdhury9Hjalti Kristinsson10Iris Ciba11Iris Ciba12Erik S. Gjessing13Katharina Mörwald14Katharina Mörwald15Julian Gomahr16Julian Gomahr17Verena Heu18Verena Heu19Daniel Weghuber20Daniel Weghuber21Anders Forslund22Anders Forslund23Anders Forslund24Peter Bergsten25Peter Bergsten26Peter Bergsten27Department of Medical Cell Biology, Uppsala University, Uppsala, SwedenDepartment of Women’s and Children’s Health, Uppsala University, Uppsala, SwedenDepartment of Pediatric Obesity, Uppsala University Children’s Hospital, Uppsala, SwedenDepartment of Medical Cell Biology, Uppsala University, Uppsala, SwedenDepartment of Medical Cell Biology, Uppsala University, Uppsala, SwedenDepartment of Medical Cell Biology, Uppsala University, Uppsala, SwedenDepartment of Women’s and Children’s Health, Uppsala University, Uppsala, SwedenDepartment of Women’s and Children’s Health, Uppsala University, Uppsala, SwedenDepartment of Pediatric Obesity, Uppsala University Children’s Hospital, Uppsala, SwedenDepartment of Medical Cell Biology, Uppsala University, Uppsala, SwedenDepartment of Medical Cell Biology, Uppsala University, Uppsala, SwedenDepartment of Women’s and Children’s Health, Uppsala University, Uppsala, SwedenDepartment of Pediatric Obesity, Uppsala University Children’s Hospital, Uppsala, SwedenDepartment of Medical Cell Biology, Uppsala University, Uppsala, SwedenDepartment of Pediatrics, Paracelsus Medical University, Salzburg, AustriaObesity Research Unit, Paracelsus Medical University, Salzburg, AustriaDepartment of Pediatrics, Paracelsus Medical University, Salzburg, AustriaObesity Research Unit, Paracelsus Medical University, Salzburg, AustriaDepartment of Pediatrics, Paracelsus Medical University, Salzburg, AustriaObesity Research Unit, Paracelsus Medical University, Salzburg, AustriaDepartment of Pediatrics, Paracelsus Medical University, Salzburg, AustriaObesity Research Unit, Paracelsus Medical University, Salzburg, AustriaDepartment of Medical Cell Biology, Uppsala University, Uppsala, SwedenDepartment of Women’s and Children’s Health, Uppsala University, Uppsala, SwedenDepartment of Pediatric Obesity, Uppsala University Children’s Hospital, Uppsala, SwedenDepartment of Medical Cell Biology, Uppsala University, Uppsala, SwedenDepartment of Women’s and Children’s Health, Uppsala University, Uppsala, SwedenDepartment of Pediatric Obesity, Uppsala University Children’s Hospital, Uppsala, SwedenBackgroundGLP-1 receptor agonists (GLP-1RA) are increasingly used to treat adolescent obesity. However, the effect on endogenous GLP-1 secretory patterns following treatment in adolescents is unknown. The GLP-1RA exenatide was shown to significantly lower BMI and 2-hour glucose in adolescents with obesity, in the placebo-controlled, randomized controlled trial Combat-JUDO. The aim of this study was to evaluate effects of weekly injections of 2 mg exenatide extended release on secretory patterns of endogenous hormones during OGTT.Subjects and MeasurementsThis study was a pre-planned sub-study of the Combat-JUDO trial, set at the Pediatric clinic at Uppsala University Hospital, Sweden and Paracelsus Medical University, Austria. 44 adolescents with obesity were included and randomized 1:1 to treatment:placebo. 19 patients in the treatment group and 18 in the placebo group completed the trial. Before and after treatment, GLP-1, glucose, insulin, glucagon and glicentin levels were measured during OGTT; DPP-4 and proinsulin were measured at fasting. A per-protocol approach was used in the analyses.ResultsExenatide treatment did not affect GLP-1 levels during OGTT. Treatment significantly lowered DPP-4, proinsulin and the proinsulin-to-insulin ratio at fasting, increased glicentin levels but did not affect insulin, C-peptide or glucagon levels during OGTT.ConclusionWeekly s.c. injections with 2 mg of exenatide maintains endogenous total GLP-1 levels and lowers circulating DPP-4 levels. This adds an argument in favor of using exenatide in the treatment of pediatric obesity.Clinical trial registrationclinicaltrials.gov, identifier NCT02794402https://www.frontiersin.org/articles/10.3389/fendo.2023.1293093/fullobesityGLP-1GLP-1 receptor analogexenatidepediatricsglycemic control |
| spellingShingle | Rasmus Stenlid Rasmus Stenlid Rasmus Stenlid Sara Y. Cerenius Quan Wen Banu Küçükemre Aydin Banu Küçükemre Aydin Hannes Manell Hannes Manell Azazul Chowdhury Hjalti Kristinsson Iris Ciba Iris Ciba Erik S. Gjessing Katharina Mörwald Katharina Mörwald Julian Gomahr Julian Gomahr Verena Heu Verena Heu Daniel Weghuber Daniel Weghuber Anders Forslund Anders Forslund Anders Forslund Peter Bergsten Peter Bergsten Peter Bergsten Adolescents with obesity treated with exenatide maintain endogenous GLP-1, reduce DPP-4, and improve glycemic control Frontiers in Endocrinology obesity GLP-1 GLP-1 receptor analog exenatide pediatrics glycemic control |
| title | Adolescents with obesity treated with exenatide maintain endogenous GLP-1, reduce DPP-4, and improve glycemic control |
| title_full | Adolescents with obesity treated with exenatide maintain endogenous GLP-1, reduce DPP-4, and improve glycemic control |
| title_fullStr | Adolescents with obesity treated with exenatide maintain endogenous GLP-1, reduce DPP-4, and improve glycemic control |
| title_full_unstemmed | Adolescents with obesity treated with exenatide maintain endogenous GLP-1, reduce DPP-4, and improve glycemic control |
| title_short | Adolescents with obesity treated with exenatide maintain endogenous GLP-1, reduce DPP-4, and improve glycemic control |
| title_sort | adolescents with obesity treated with exenatide maintain endogenous glp 1 reduce dpp 4 and improve glycemic control |
| topic | obesity GLP-1 GLP-1 receptor analog exenatide pediatrics glycemic control |
| url | https://www.frontiersin.org/articles/10.3389/fendo.2023.1293093/full |
| work_keys_str_mv | AT rasmusstenlid adolescentswithobesitytreatedwithexenatidemaintainendogenousglp1reducedpp4andimproveglycemiccontrol AT rasmusstenlid adolescentswithobesitytreatedwithexenatidemaintainendogenousglp1reducedpp4andimproveglycemiccontrol AT rasmusstenlid adolescentswithobesitytreatedwithexenatidemaintainendogenousglp1reducedpp4andimproveglycemiccontrol AT saraycerenius adolescentswithobesitytreatedwithexenatidemaintainendogenousglp1reducedpp4andimproveglycemiccontrol AT quanwen adolescentswithobesitytreatedwithexenatidemaintainendogenousglp1reducedpp4andimproveglycemiccontrol AT banukucukemreaydin adolescentswithobesitytreatedwithexenatidemaintainendogenousglp1reducedpp4andimproveglycemiccontrol AT banukucukemreaydin adolescentswithobesitytreatedwithexenatidemaintainendogenousglp1reducedpp4andimproveglycemiccontrol AT hannesmanell adolescentswithobesitytreatedwithexenatidemaintainendogenousglp1reducedpp4andimproveglycemiccontrol AT hannesmanell adolescentswithobesitytreatedwithexenatidemaintainendogenousglp1reducedpp4andimproveglycemiccontrol AT azazulchowdhury adolescentswithobesitytreatedwithexenatidemaintainendogenousglp1reducedpp4andimproveglycemiccontrol AT hjaltikristinsson adolescentswithobesitytreatedwithexenatidemaintainendogenousglp1reducedpp4andimproveglycemiccontrol AT irisciba adolescentswithobesitytreatedwithexenatidemaintainendogenousglp1reducedpp4andimproveglycemiccontrol AT irisciba adolescentswithobesitytreatedwithexenatidemaintainendogenousglp1reducedpp4andimproveglycemiccontrol AT eriksgjessing adolescentswithobesitytreatedwithexenatidemaintainendogenousglp1reducedpp4andimproveglycemiccontrol AT katharinamorwald adolescentswithobesitytreatedwithexenatidemaintainendogenousglp1reducedpp4andimproveglycemiccontrol AT katharinamorwald adolescentswithobesitytreatedwithexenatidemaintainendogenousglp1reducedpp4andimproveglycemiccontrol AT juliangomahr adolescentswithobesitytreatedwithexenatidemaintainendogenousglp1reducedpp4andimproveglycemiccontrol AT juliangomahr adolescentswithobesitytreatedwithexenatidemaintainendogenousglp1reducedpp4andimproveglycemiccontrol AT verenaheu adolescentswithobesitytreatedwithexenatidemaintainendogenousglp1reducedpp4andimproveglycemiccontrol AT verenaheu adolescentswithobesitytreatedwithexenatidemaintainendogenousglp1reducedpp4andimproveglycemiccontrol AT danielweghuber adolescentswithobesitytreatedwithexenatidemaintainendogenousglp1reducedpp4andimproveglycemiccontrol AT danielweghuber adolescentswithobesitytreatedwithexenatidemaintainendogenousglp1reducedpp4andimproveglycemiccontrol AT andersforslund adolescentswithobesitytreatedwithexenatidemaintainendogenousglp1reducedpp4andimproveglycemiccontrol AT andersforslund adolescentswithobesitytreatedwithexenatidemaintainendogenousglp1reducedpp4andimproveglycemiccontrol AT andersforslund adolescentswithobesitytreatedwithexenatidemaintainendogenousglp1reducedpp4andimproveglycemiccontrol AT peterbergsten adolescentswithobesitytreatedwithexenatidemaintainendogenousglp1reducedpp4andimproveglycemiccontrol AT peterbergsten adolescentswithobesitytreatedwithexenatidemaintainendogenousglp1reducedpp4andimproveglycemiccontrol AT peterbergsten adolescentswithobesitytreatedwithexenatidemaintainendogenousglp1reducedpp4andimproveglycemiccontrol |